Status:

COMPLETED

A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE1

Brief Summary

This is a Phase I Dose-Escalation Study of BMS641988 in Patients with Castration-Resistant Prostate Cancer.

Eligibility Criteria

Inclusion

  • Advanced castration-resistant prostate carcinoma with progressive disease
  • At least 4 weeks must have elapsed from major surgery
  • Patient must be available for follow-up
  • Adequate liver and kidney function
  • Adequate blood values

Exclusion

  • Uncontrolled or significant heart disease
  • History of seizures
  • History of head injury, loss of consciousness, or stroke
  • Patients undergoing alcohol withdrawal
  • Any concurrent cancer
  • A serious uncontrolled medical disorder or active infection
  • Inability to swallow tablets

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2009

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT00326586

Start Date

May 1 2006

End Date

March 1 2009

Last Update

January 25 2011

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

Baltimore, Maryland, United States, 21231

2

Memorial Sloan-Kettering Cancer Center

New York, New York, United States, 10021

3

University Of Wisconsin Hospital And Clinics Laboratory

Madison, Wisconsin, United States, 53792